<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: <z:chebi fb="1" ids="36809">Tricyclic antidepressants</z:chebi> are known to induce <z:hpo ids='HP_0011675'>cardiac arrhythmias</z:hpo> at therapeutic or supratherapeutic doses </plain></SENT>
<SENT sid="1" pm="."><plain>The <z:chebi fb="1" ids="36809">tricyclic antidepressant</z:chebi>, <z:chebi fb="0" ids="2666">amitriptyline</z:chebi>, is reported to induce ST segment elevation in the right precordial electrocardiogram (ECG) leads, thus unmasking <z:e sem="disease" ids="C1142166" disease_type="Disease or Syndrome" abbrv="SUNDS">Brugada syndrome</z:e> (BrS) </plain></SENT>
<SENT sid="2" pm="."><plain>The mechanism by which antidepressants induce the BrS phenotype and associated <z:hpo ids='HP_0001699'>sudden death</z:hpo> is not well established </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS AND RESULTS: Action potentials (AP) were simultaneously recorded from epicardial and endocardial sites of isolated coronary-perfused canine right ventricular wedge preparations, together with a transmural pseudo-ECG </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="2666">Amitriptyline</z:chebi> alone (0.2 μM-1 mM) failed to induce a BrS phenotype </plain></SENT>
<SENT sid="5" pm="."><plain>NS5806 (8 μM), a transient outward <z:chebi fb="120" ids="26216">potassium</z:chebi> channel current (I(to) ) <z:chebi fb="4" ids="48705">agonist</z:chebi>, was used to produce an outward shift of current mimicking a genetic predisposition to BrS </plain></SENT>
<SENT sid="6" pm="."><plain>In the presence of NS5806, a therapeutic concentration of <z:chebi fb="0" ids="2666">amitriptyline</z:chebi> (0.2 μM) accentuated the epicardial AP notch leading to ST-segment elevation of the ECG </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo>-or-none repolarization at some epicardial sites but not others gave rise to phase-2-reentry and polymorphic <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> (VT) in 6 of 9 preparations </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="6046">Isoproterenol</z:chebi> (100 nM) or <z:chebi fb="0" ids="28593">quinidine</z:chebi> (10 μM) reversed the effects of <z:chebi fb="0" ids="2666">amitriptyline</z:chebi> aborting phase 2 reentry and VT (4/4) </plain></SENT>
<SENT sid="9" pm="."><plain>Using voltage-clamp techniques applied to isolated canine ventricular myocytes, 0.2 μM <z:chebi fb="0" ids="2666">amitriptyline</z:chebi> was shown to produce use-dependent inhibition of <z:chebi fb="199" ids="26708">sodium</z:chebi> channel current (I(Na) ), without significantly affecting I(to) (n = 5) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Our data suggest that <z:chebi fb="0" ids="2666">amitriptyline</z:chebi>-induced inhibition of I(Na) unmasks the Brugada ECG phenotype and facilitates development of an arrhythmogenic substrate only in the setting of a genetic predisposition by creating repolarization <z:hpo ids='HP_0001425'>heterogeneities</z:hpo> that give rise to phase 2 reentry and VT </plain></SENT>
</text></document>